Clinical Trials

Accrual Status
Limit to SWOG Trials

1040 Results

Closed
Phase
Accrual
57%
Published
SWOG Clinical Trial Number
SWOG-9150

Evaluation of Topotecan in Gastric Cancer, Phase II

Research Committee(s)
Gastrointestinal Cancer
Activated
07-15-1992
Closed
10-15-1993
Closed
Phase
Accrual
58%
Published
SWOG Clinical Trial Number
SWOG-8955

Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II

Research Committee(s)
Genitourinary Cancer
Activated
06-15-1992
Closed
11-01-1993
Closed
Phase
Accrual
35%
SWOG Clinical Trial Number
SWOG-9147

Evaluation of Tamoxifen in Desmoid Tumors, Phase II

Activated
06-01-1992
Closed
08-01-1996
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9116
Closed
Phase
Accrual
62%
Published
SWOG Clinical Trial Number
SWOG-9124

Evaluation of Edatrexate (EDX) in Patients with Relapsed or Refractory Germ Cell Tumors, Phase II

Research Committee(s)
Genitourinary Cancer
Activated
06-01-1992
Closed
09-01-1996
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9032
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-9135

A Phase II Trial of Taxol and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Pancreatic Adenocarcinoma

Research Committee(s)
Gastrointestinal Cancer
Activated
06-01-1992
Closed
01-15-1993
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9122
Closed
Phase
Accrual
53%
Published
SWOG Clinical Trial Number
SWOG-9138
Closed
Phase
Accrual
46%
Published
SWOG Clinical Trial Number
SWOG-9058
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
SWOG-9015
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9019
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9051
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9151

Evaluation of Topotecan in Hepatoma, Phase II

Research Committee(s)
Gastrointestinal Cancer
Activated
02-01-1992
Closed
06-15-1993
Closed
Phase
Accrual
14%
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9139